MEG is a multi-disciplinary group, consisting of a team of researchers across a broad range of science, mainly chemistry and related fields, exploring the next generation of molecular architectures.
With the vision of addressing significant global issues and to improve health and economic well-being, MEG uses its combined knowledge to design molecular structures with real applications.
Despite the success of existing clinical metal compounds (such as cisplatin, a well-known and understood platinum-based compound for the treatment of cancer), further developments in drug therapy are necessary to overcome their drawbacks, primarily their high toxicity, which causes unwanted side-effects in the human body.
This project seeks to develop a new class of anti-cancer gold drugs which are less toxic towards non-cancerous cells, thus minimising unwanted side-effects. This project intends to provide an alternative treatment for cancer patients requiring life-extending options or an ultimate cure for non-terminal cancer patients.
The major innovation of this project lies in combining for the first time the properties of flavonoids, a common antioxidant component in the human diet and a versatile foundation for anti-cancer drugs, and with a gold fragment to prepare novel gold complexes with notably improved biological properties.
- Dr Neda Mirzadeh (discipline leader)
- Dr Steven Privér
- Dr Srinivasareddy Telukutla
- Dr Ravi Shukla
- Dr Ramakrishna Sistla
- Professor Marin Bennett (Australia)
- Professor Alan Bond (Australia)
- Dr Lakshmi Kantham (India)
- Professor Vivian Yam (Hong Kong)
- Professor Sandy Blake (England)
- Dr Jörg Wagler (Germany)
- Professor Salvy Russo (Australia)
- Dr Daniel Drumm (Australia)
PhD positions available
Interested students and researchers should contact Dr Neda Mirzadeh for possible candidature/collaboration.
- N. Mirzadeh, M. A. Bennett, S. K. Bhargava, “Cycloaurated complexes of aryl Carbanions: Digold(I), Digold(II) and Beyond”, Coord. Chem. Rev., 2013, 257, 2250.
- N. Mirzadeh, S. H. Privér, A. Abraham, R. Schukla, V. Bansal, S. Bhargava, “Linking flavonoids to gold: a new family of gold compounds for potential therapeutic applications”, Eur. J. Inorg. Chem. 2015, 4275.
- A. E. O’Connor, N. Mirzadeh, S. K. Bhargava. T. Easun, M. Schroder, A. J. Blake, “Aurophilicity under pressure: a combined crystallographic and in-situ spectroscopic study”, Chem. Comm. 2016, 52, 6769.
- N. P. Kumar, P. Sharma, T. S. Reddy, S. Nekkanti, N. Shankaraiah, G. Lalita, S. Sujanakumari, S. K. Bhargava, V. G. M. Naidu, A. Kamal, “Synthesis of 2,3,6,7-tetramethoxyphenanthren-9-amine: An efficient precursor to access new 4-aza-2,3-dihydropyridophenanthrenes as apoptosis inducing agents”, Eur. J. Med. Chem. 2017, 127, 305.
- M. A. Bennett, S. K. Bhargava, E. C. –C. Cheng, W. H. Lam, T. K. –M. Lee, S. H. Privér, J. Wagler, A. C. Willis, V. W. –W., Yam. “Unprecedented Near-Infrared (NIR) Emission in Diplatinum(III) (d7−d7) Complexes at Room Temperature”, J. Am. Chem. Soc., 2010, 132, 7094.